Kalaris Therapeutics, Inc. (KLRS)
 NASDAQ: KLRS · Real-Time Price · USD
 5.11
 +0.37 (7.81%)
  At close: Oct 31, 2025, 4:00 PM EDT
5.03
 -0.08 (-1.57%)
  After-hours: Oct 31, 2025, 4:00 PM EDT
Kalaris Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Kalaris Therapeutics stock has a target of 23, which predicts a 350.10% increase from the current stock price of 5.11.
Price Target: $23 (+350.10%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 3, 2025.
Analyst Ratings
The average analyst rating for Kalaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | 
|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 
| Buy | 1 | 1 | 1 | 
| Hold | 0 | 0 | 0 | 
| Sell | 0 | 0 | 0 | 
| Strong Sell | 0 | 0 | 0 | 
| Total | 1 | 2 | 2 | 
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date | 
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +350.10% | Sep 3, 2025 | 
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 8, 2025 | 
Financial Forecast
Revenue This Year
 n/a 
 Revenue Next Year
 n/a 
 EPS This Year
 -3.72 
 from -10.44
EPS Next Year
 -2.54 
 from -3.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a | 
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - | 
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | -2.79 | -2.14 | |
| Avg | -3.72 | -2.54 | |
| Low | -4.44 | -2.74 | 
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - | 
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.